EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers

Taigo Kato, Shugo Yajima, Yoshiaki Nakamura, Shin Kobayashi, Hideaki Miyake

International Journal of Urology · 2025

DOI: 10.1111/iju.70215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2025. Verfasst von Taigo Kato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Neoplasm, Residual, Circulating Tumor DNA, Neoplasm Recurrence, Local, Urogenital Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While the clinical outcome for patients with resectable solid tumors has improved in recent years, the risk of postoperative recurrence underscores the need for effective monitoring in cancer patients. Molecular residual disease (MRD) refers to the presence of microscopic cancer that remains undetectable on conventional imaging or pathology. Because of the rapid advancement in circulating tumor DNA (ctDNA) analysis using next‐generation sequencing technology, MRD testing using ctDNA has demonstrated significant potential for predicting recurrence in various types of cancer. Similar data are found in genitourinary (GU) cancer, and pivotal research has gradually shed light on the importance of MRD in predicting tumor recurrence. To address these critical advancements in MRD testing in GU cancers, we conducted a review of the clinical utility of MRD testing for GU cancers. In this review, we provide an overview of the potential utility of ctDNA‐based MRD detection for GU cancers and highlight several ongoing clinical trials for the development of MRD‐guided treatments with ctDNA. ctDNA‐based MRD testing has the potential to personalize cancer precision medicine in GU cancers, guiding adjuvant therapy decisions, improving early detection of recurrence, and refining surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualCirculating Tumor DNANeoplasm Recurrence, LocalUrogenital NeoplasmsHumansHigh-Throughput Nucleotide SequencingBiomarkers, TumorPrecision Medicine

Stichwörter der Autor:innen

circulating tumor DNAgenitourinary cancermolecular residual disease

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Department of Hepato-Biliary-Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Zitieren

APA

Kato, T., Yajima, S., Nakamura, Y., Kobayashi, S., & Miyake, H. (2025). Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers. International Journal of Urology. https://doi.org/10.1111/iju.70215

Vancouver

Kato T, Yajima S, Nakamura Y, Kobayashi S, Miyake H. Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers. International Journal of Urology. 2025. doi:10.1111/iju.70215

BibTeX
@article{Kato2025,
  author = {Kato, Taigo and Yajima, Shugo and Nakamura, Yoshiaki and Kobayashi, Shin and Miyake, Hideaki},
  title = {Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70215}
}
Kostenlos starten →